Skip to main content
Erschienen in: Supportive Care in Cancer 3/2012

01.03.2012 | Original Article

Comparing baseline symptom severity and demographics over two time periods in an outpatient palliative radiotherapy clinic

verfasst von: Luluel Khan, Justin Kwong, Janet Nguyen, Edward Chow, Liying Zhang, Shaelyn Culleton, Liang Zeng, Florencia Jon, May Tsao, Elizabeth Barnes, Cyril Danjoux, Arjun Sahgal, Lori Holden

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The primary objective of this study was to compare the symptom severity in two different patient populations assessed in an outpatient palliative radiotherapy clinic over two time periods spanning 10 years. The secondary objective was to assess any changes in the baseline demographics of these patients.

Methods

Data were collected from 1999 to 2009. Upon initial presentation to the clinic, the Edmonton Symptom Assessment Scale (ESAS) was administered to patients to capture symptom severity. This validated assessment tool asks patients to score their level of pain, tiredness, nausea, depression, anxiety, drowsiness, loss of appetite, well-being, and dyspnea on an 11-point Likert scale. Differences between the two patient groups were assessed using chi-squared analysis and Wilcoxon rank–sum tests. A p value of <0.05 was considered significant.

Results

A total of 1,439 patients completed the ESAS from 1999 to 2009. Patients were divided into two time periods 1999–2002 (n = 689) and 2006–2009 (n = 750). Pain, depression, nausea, fatigue, anxiety, drowsiness, and dyspnea were significantly better in 2006–2009 (p < 0.0001). Loss of appetite was not statistically different between the two time periods (p = 0.236). Significantly more patients with genitourinary cancers (p = 0.03) or a referral for a mass (p < 0.0001) were seen in 2006–2009. More patients with breast cancer (p = 0.04) and bone pain (p = 0.0002) were seen in 1999–2002. The median age was significantly higher (70 years vs. 68 years, p = 0.03) for patients seen in 2006–2009. No significant differences were seen in performance status or gender between the two groups.

Conclusion

There have been statistically significant lower scores in the severity of the majority of symptoms as scored by the latter patient cohort; however, whether this difference in magnitude is clinically significant is debatable. The reason for referral and demographics in patients sent for palliative radiotherapy has changed over a 10-year period. This may be a reflection of the changes in systemic therapies and improvements in supportive care for patients with advanced cancer.
Literatur
1.
Zurück zum Zitat Ferris FD, Bruera E, Cherny N et al (2009) Palliative cancer care a decade later: accomplishments, the need, next steps–from the American Society of Clinical Oncology. J Clin Oncol 27(18):3052–3058PubMedCrossRef Ferris FD, Bruera E, Cherny N et al (2009) Palliative cancer care a decade later: accomplishments, the need, next steps–from the American Society of Clinical Oncology. J Clin Oncol 27(18):3052–3058PubMedCrossRef
2.
Zurück zum Zitat Portenoy RK, Thaler HT, Kornblith AB et al (1994) Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3(3):183–189PubMedCrossRef Portenoy RK, Thaler HT, Kornblith AB et al (1994) Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3(3):183–189PubMedCrossRef
3.
Zurück zum Zitat Teunissen SC, Wesker W, Kruitwagen C et al (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34(1):94–104PubMedCrossRef Teunissen SC, Wesker W, Kruitwagen C et al (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34(1):94–104PubMedCrossRef
4.
Zurück zum Zitat Conill C, Verger E, Henriquez I et al (1997) Symptom prevalence in the last week of life. J Pain Symptom Manage 14(6):328–331PubMedCrossRef Conill C, Verger E, Henriquez I et al (1997) Symptom prevalence in the last week of life. J Pain Symptom Manage 14(6):328–331PubMedCrossRef
5.
Zurück zum Zitat Lo RS, Ding A, Chung TK et al (1999) Prospective study of symptom control in 133 cases of palliative care inpatients in Shatin Hospital. Palliat Med 13(4):335–340PubMedCrossRef Lo RS, Ding A, Chung TK et al (1999) Prospective study of symptom control in 133 cases of palliative care inpatients in Shatin Hospital. Palliat Med 13(4):335–340PubMedCrossRef
6.
Zurück zum Zitat Ng K, Von Gunten CF (1998) Symptoms and attitudes of 100 consecutive patients admitted to an acute hospice/palliative care unit. J Pain Symptom Manage 16(5):307–316PubMedCrossRef Ng K, Von Gunten CF (1998) Symptoms and attitudes of 100 consecutive patients admitted to an acute hospice/palliative care unit. J Pain Symptom Manage 16(5):307–316PubMedCrossRef
7.
Zurück zum Zitat Potter J, Hami F, Bryan T et al (2003) Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med 17(4):310–314PubMedCrossRef Potter J, Hami F, Bryan T et al (2003) Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med 17(4):310–314PubMedCrossRef
8.
Zurück zum Zitat Selby D, Cascella A, Gardiner K et al (2010) A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton Symptom Assessment System. J Pain Symptom Manage 39(2):241–249PubMedCrossRef Selby D, Cascella A, Gardiner K et al (2010) A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton Symptom Assessment System. J Pain Symptom Manage 39(2):241–249PubMedCrossRef
9.
Zurück zum Zitat Smith TJ, Schnipper LJ (1998) The American Society of Clinical Oncology program to improve end-of-life care. J Palliat Med 1(3):221–230PubMedCrossRef Smith TJ, Schnipper LJ (1998) The American Society of Clinical Oncology program to improve end-of-life care. J Palliat Med 1(3):221–230PubMedCrossRef
10.
Zurück zum Zitat Bradley N, Davis L, Chow E (2005) Symptom distress in patients attending an outpatient palliative radiotherapy clinic. J Pain Symptom Manage 30(2):123–131PubMedCrossRef Bradley N, Davis L, Chow E (2005) Symptom distress in patients attending an outpatient palliative radiotherapy clinic. J Pain Symptom Manage 30(2):123–131PubMedCrossRef
11.
Zurück zum Zitat Delgado-Guay M, Parsons HA, Li Z et al (2009) Symptom distress in advanced cancer patients with anxiety and depression in the palliative care setting. Support Care Cancer 17(5):573–579PubMedCrossRef Delgado-Guay M, Parsons HA, Li Z et al (2009) Symptom distress in advanced cancer patients with anxiety and depression in the palliative care setting. Support Care Cancer 17(5):573–579PubMedCrossRef
12.
Zurück zum Zitat Hotopf M, Chidgey J, Addington-Hall J et al (2002) Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 16(2):81–97PubMedCrossRef Hotopf M, Chidgey J, Addington-Hall J et al (2002) Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 16(2):81–97PubMedCrossRef
13.
Zurück zum Zitat Vignaroli E, Pace EA, Willey J et al (2006) The Edmonton Symptom Assessment System as a screening tool for depression and anxiety. J Palliat Med 9(2):296–303PubMedCrossRef Vignaroli E, Pace EA, Willey J et al (2006) The Edmonton Symptom Assessment System as a screening tool for depression and anxiety. J Palliat Med 9(2):296–303PubMedCrossRef
14.
Zurück zum Zitat Fan G, Hadi S, Chow E (2007) Symptom clusters in patients with advanced-stage cancer referred for palliative radiation therapy in an outpatient setting. Support Cancer Ther 4(3):157–162PubMedCrossRef Fan G, Hadi S, Chow E (2007) Symptom clusters in patients with advanced-stage cancer referred for palliative radiation therapy in an outpatient setting. Support Cancer Ther 4(3):157–162PubMedCrossRef
15.
Zurück zum Zitat Higginson IJ, Finlay I, Goodwin DM et al (2002) Do hospital-based palliative teams improve care for patients or families at the end of life? J Pain Symptom Manage 23(2):96–106PubMedCrossRef Higginson IJ, Finlay I, Goodwin DM et al (2002) Do hospital-based palliative teams improve care for patients or families at the end of life? J Pain Symptom Manage 23(2):96–106PubMedCrossRef
16.
Zurück zum Zitat Byock I (2000) Completing the continuum of cancer care: integrating life-prolongation and palliation. CA Cancer J Clin 50(2):123–132PubMedCrossRef Byock I (2000) Completing the continuum of cancer care: integrating life-prolongation and palliation. CA Cancer J Clin 50(2):123–132PubMedCrossRef
17.
Zurück zum Zitat Lagman R, Walsh D (2005) Integration of palliative medicine into comprehensive cancer care. Semin Oncol 32(2):134–138PubMedCrossRef Lagman R, Walsh D (2005) Integration of palliative medicine into comprehensive cancer care. Semin Oncol 32(2):134–138PubMedCrossRef
19.
Zurück zum Zitat Butt Z, Wagner LI, Beaumont JL et al (2008) Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage 35(1):20–30PubMedCrossRef Butt Z, Wagner LI, Beaumont JL et al (2008) Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage 35(1):20–30PubMedCrossRef
20.
Zurück zum Zitat Reddy S, Bruera E, Pace E et al (2007) Clinically important improvement in the intensity of fatigue in patients with advanced cancer. J Palliat Med 10(5):1068–1075PubMedCrossRef Reddy S, Bruera E, Pace E et al (2007) Clinically important improvement in the intensity of fatigue in patients with advanced cancer. J Palliat Med 10(5):1068–1075PubMedCrossRef
21.
Zurück zum Zitat International Bone Metastases Consensus Working Party (2001) International bone metastases consensus on endpoint measurements for future clinical trials: proceedings of the first survey and meeting (work in progress) International Bone Metastases Consensus Working Party (2001). Clin Oncol (R Coll Radiol) 13(2):82–84 International Bone Metastases Consensus Working Party (2001) International bone metastases consensus on endpoint measurements for future clinical trials: proceedings of the first survey and meeting (work in progress) International Bone Metastases Consensus Working Party (2001). Clin Oncol (R Coll Radiol) 13(2):82–84
22.
Zurück zum Zitat Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743PubMedCrossRef Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743PubMedCrossRef
23.
Zurück zum Zitat Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792–799PubMedCrossRef Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792–799PubMedCrossRef
24.
Zurück zum Zitat Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24(18):2786–2792PubMedCrossRef Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24(18):2786–2792PubMedCrossRef
25.
Zurück zum Zitat Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090PubMedCrossRef Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090PubMedCrossRef
26.
Zurück zum Zitat Chow E, Holden L, Danjoux C et al (2004) Successful salvage using percutaneous vertebroplasty in cancer patients with painful spinal metastases or osteoporotic compression fractures. Radiother Oncol 70(3):265–267PubMedCrossRef Chow E, Holden L, Danjoux C et al (2004) Successful salvage using percutaneous vertebroplasty in cancer patients with painful spinal metastases or osteoporotic compression fractures. Radiother Oncol 70(3):265–267PubMedCrossRef
27.
Zurück zum Zitat Mayer EK, Bottle A, Darzi A et al (2010) The volume-mortality relation for radical cystectomy in England: retrospective analysis of hospital episode statistics. BMJ 340:1128CrossRef Mayer EK, Bottle A, Darzi A et al (2010) The volume-mortality relation for radical cystectomy in England: retrospective analysis of hospital episode statistics. BMJ 340:1128CrossRef
28.
Zurück zum Zitat Chung A, Schoder H, Sampson M et al (2010) Incidental breast lesions identified by 18F-fluorodeoxyglucose-positron emission tomography. Ann Surg Oncol 17:2119–2125PubMedCrossRef Chung A, Schoder H, Sampson M et al (2010) Incidental breast lesions identified by 18F-fluorodeoxyglucose-positron emission tomography. Ann Surg Oncol 17:2119–2125PubMedCrossRef
29.
Zurück zum Zitat Kucharczyk MJ, Menezes RJ, McGregor A, et al (2010) Assessing the impact of incidental findings in a lung cancer screening study by using low-dose computed tomography. Can Assoc Radiol J (in press) Kucharczyk MJ, Menezes RJ, McGregor A, et al (2010) Assessing the impact of incidental findings in a lung cancer screening study by using low-dose computed tomography. Can Assoc Radiol J (in press)
30.
Zurück zum Zitat Garyali A, Palmer JL, Yennurajalingam S et al (2006) Errors in symptom intensity self-assessment by patients receiving outpatient palliative care. J Palliat Med 9(5):1059–1065PubMedCrossRef Garyali A, Palmer JL, Yennurajalingam S et al (2006) Errors in symptom intensity self-assessment by patients receiving outpatient palliative care. J Palliat Med 9(5):1059–1065PubMedCrossRef
Metadaten
Titel
Comparing baseline symptom severity and demographics over two time periods in an outpatient palliative radiotherapy clinic
verfasst von
Luluel Khan
Justin Kwong
Janet Nguyen
Edward Chow
Liying Zhang
Shaelyn Culleton
Liang Zeng
Florencia Jon
May Tsao
Elizabeth Barnes
Cyril Danjoux
Arjun Sahgal
Lori Holden
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1120-1

Weitere Artikel der Ausgabe 3/2012

Supportive Care in Cancer 3/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.